These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 22014257)

  • 1. Buprenorphine Maintenance for Opioid Dependence in Public Sector Healthcare: Benefits and Barriers.
    Duncan LG; Mendoza S; Hansen H
    J Addict Med Ther Sci; 2015; 1(2):31-36. PubMed ID: 27088135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot randomized controlled trial of a hospital-based substance use treatment and recovery team (START) to improve initiation of medication for alcohol or opioid use disorder and linkage to follow-up care.
    Ober AJ; Osilla KC; Klein DJ; Burgette LF; Leamon I; Mazer MW; Messineo G; Collier S; Korouri S; Watkins KE; Ishak W; Nuckols T; Danovitch I
    J Subst Use Addict Treat; 2023 Jul; 150():209063. PubMed ID: 37156424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine.
    Du CX; Shi J; Tetrault JM; Madden LM; Barry DT
    Fam Pract; 2022 Mar; 39(2):234-240. PubMed ID: 34893825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiation and engagement as mechanisms for change caused by collaborative care in opioid and alcohol use disorders.
    Setodji CM; Watkins KE; Hunter SB; McCullough C; Stein BD; Osilla KC; Ober AJ
    Drug Alcohol Depend; 2018 Nov; 192():67-73. PubMed ID: 30223190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustaining alcohol and opioid use disorder treatment in primary care: a mixed methods study.
    Hunter SB; Ober AJ; McCullough CM; Storholm ED; Iyiewuare PO; Pham C; Watkins KE
    Implement Sci; 2018 Jun; 13(1):83. PubMed ID: 29914524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient predictors of substance use disorder treatment initiation in primary care.
    Ober AJ; Watkins KE; McCullough CM; Setodji CM; Osilla K; Hunter SB
    J Subst Abuse Treat; 2018 Jul; 90():64-72. PubMed ID: 29866385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing and improving organizational readiness to implement substance use disorder treatment in primary care: findings from the SUMMIT study.
    Ober AJ; Watkins KE; Hunter SB; Ewing B; Lamp K; Lind M; Becker K; Heinzerling K; Osilla KC; Diamant AL; Setodji CM
    BMC Fam Pract; 2017 Dec; 18(1):107. PubMed ID: 29268702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary care models for treating opioid use disorders: What actually works? A systematic review.
    Lagisetty P; Klasa K; Bush C; Heisler M; Chopra V; Bohnert A
    PLoS One; 2017; 12(10):e0186315. PubMed ID: 29040331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An organizational readiness intervention and randomized controlled trial to test strategies for implementing substance use disorder treatment into primary care: SUMMIT study protocol.
    Ober AJ; Watkins KE; Hunter SB; Lamp K; Lind M; Setodji CM
    Implement Sci; 2015 May; 10():66. PubMed ID: 25951953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Community-wide measures of wellness in a remote First Nations community experiencing opioid dependence: evaluating outpatient buprenorphine-naloxone substitution therapy in the context of a First Nations healing program.
    Kanate D; Folk D; Cirone S; Gordon J; Kirlew M; Veale T; Bocking N; Rea S; Kelly L
    Can Fam Physician; 2015 Feb; 61(2):160-5. PubMed ID: 25821874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maternal opioid drug use during pregnancy and its impact on perinatal morbidity, mortality, and the costs of medical care in the United States.
    Whiteman VE; Salemi JL; Mogos MF; Cain MA; Aliyu MH; Salihu HM
    J Pregnancy; 2014; 2014():906723. PubMed ID: 25254116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Entry into primary care-based buprenorphine treatment is associated with identification and treatment of other chronic medical problems.
    Rowe TA; Jacapraro JS; Rastegar DA
    Addict Sci Clin Pract; 2012 Oct; 7(1):22. PubMed ID: 23186008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A urinalysis-based comparative study of treatment adherence on buprenorphine and buprenorphine/naloxone combination used as opioid substitution therapy.
    Pal Singh Balhara Y; Jain R
    Innov Clin Neurosci; 2012 Jul; 9(7-8):24-9. PubMed ID: 22984649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case series of buprenorphine/naloxone treatment in a primary care practice.
    Doolittle B; Becker W
    Subst Abus; 2011 Oct; 32(4):262-5. PubMed ID: 22014257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
    Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S
    Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The implementation of buprenorphine/naloxone in college health practice.
    DeMaria PA; Patkar AA
    J Am Coll Health; 2008; 56(4):391-3. PubMed ID: 18316282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of buprenorphine/naloxone dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: a retrospective study of US public and private health care claims.
    Khemiri A; Kharitonova E; Zah V; Ruby J; Toumi M
    Postgrad Med; 2014 Sep; 126(5):113-20. PubMed ID: 25295655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.